Michael Wei

4PUBLICATIONS
37CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 02, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Lihua E Budde, Huilai Zhang, Won-Seog Kim

|Apr 25, 2025
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

Junyi Li, Michael Z Liao, Justin Wilkins

|Sep 27, 2024
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.

Chi-Chung Li, Brendan Bender, Justin Wilkins

|May 29, 2024
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Brendan Bender, Chi-Chung Li, Mathilde Marchand

Pageof 1

Frequent Collaborators

3 joint publications

Chi-Chung Li

3 joint publications

Bei Wang

3 joint publications

Shweta Vadhavkar

3 joint publications

Shen Yin